Efficacy and safety of once-daily oral semaglutide [amount hidden] compared with [amount hidden] in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial

What Was Tested

The paper reports a study of Semaglutide, published as a randomized controlled trial.

Who Took Part

The abstract describes 14 adults taking part.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

The primary endpoint was change in HbA1c from baseline to week 52, evaluated with a treatment policy estimand in the intention-to-treat population.

How the Study Was Run

The design is described as randomized, double-blind and multicenter.

The adults were allocated by chance, so the Semaglutide group and the comparison group should start out alike.

As a double-blind Semaglutide study, the assignments were hidden from both participants and investigators until the end.

Running at several centres spread the Semaglutide study over different clinics and patient groups.

This trial is registered with ClinicalTrials.gov, NCT04707469, and the European Clinical Trials register, EudraCT 2020-000299-39, and is complete.

What Was Measured

Topics PubMed links to this paper include Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glucagon-Like Peptides and Semaglutide.

What This Means in Plain Language

The paper is a randomized, double-blind and multicenter study of Semaglutide in 14 adults.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2023 (Lancet (London, England)), a journal based in England.

More context: the Semaglutide compound page, all human trials.